<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20250129091008
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20250129091008" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 29 Jan 2025 14:10:09 +0000</lastbuilddate>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39875555/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>Anthracyclines are the cornerstone of treatment for many malignancies. However, anthracycline cardiotoxicity is a considerable concern given that it can compromise the clinical effectiveness of the treatment and patient survival despite early discontinuation of therapy or dose reduction. Patients with cancer receiving anthracycline treatment can have a reduction in their quality of life and likelihood of survival due to cardiotoxicity, irrespective of their oncological prognosis. Increasing...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 28. doi: 10.1038/s41569-025-01126-1. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Anthracyclines are the cornerstone of treatment for many malignancies. However, anthracycline cardiotoxicity is a considerable concern given that it can compromise the clinical effectiveness of the treatment and patient survival despite early discontinuation of therapy or dose reduction. Patients with cancer receiving anthracycline treatment can have a reduction in their quality of life and likelihood of survival due to cardiotoxicity, irrespective of their oncological prognosis. Increasing knowledge about anthracycline cardiotoxicity has enabled the identification of patients who are candidates for anthracycline regimens and those who might develop anthracycline-induced cardiomyopathy. Anthracycline cardiotoxicity is a unique and evolving phenomenon that begins with myocardial cell damage, progresses to reduced left ventricular ejection fraction, and culminates in symptomatic heart failure if it is not promptly detected and treated. Early risk stratification can be guided by imaging or biomarkers. In this Review, we present a comprehensive and clinically useful approach to cardiomyopathy related to anthracycline therapy, encompassing its epidemiology, definition, mechanisms, novel classifications, risk factors and patient risk stratification, diagnostic approaches (including imaging and biomarkers), treatment guidelines algorithms, and the role of new cardioprotective drugs that are used for the treatment of heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39875555/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39875555</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01126-1>10.1038/s41569-025-01126-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39875555</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Iacopo Fabiani</dc:creator>
<dc:creator>Michela Chianca</dc:creator>
<dc:creator>Carlo Maria Cipolla</dc:creator>
<dc:creator>Daniela Maria Cardinale</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment</dc:title>
<dc:identifier>pmid:39875555</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01126-1</dc:identifier>
</item>
<item>
<title>The molecular structure of LDL has finally been elucidated</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39875554/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 28. doi: 10.1038/s41569-025-01128-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39875554/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39875554</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01128-z>10.1038/s41569-025-01128-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39875554</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Gilles C Lambert</dc:creator>
<dc:creator>Simon G Pfisterer</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>The molecular structure of LDL has finally been elucidated</dc:title>
<dc:identifier>pmid:39875554</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01128-z</dc:identifier>
</item>
<item>
<title>Obesity alters cholesterol homeostasis in regulatory T cells of visceral adipose tissue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39875553/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 28. doi: 10.1038/s41569-025-01129-y. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39875553/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39875553</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01129-y>10.1038/s41569-025-01129-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39875553</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Obesity alters cholesterol homeostasis in regulatory T cells of visceral adipose tissue</dc:title>
<dc:identifier>pmid:39875553</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01129-y</dc:identifier>
</item>
<item>
<title>Colchicine in acute coronary syndromes: the present and the possible future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39875552/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 28. doi: 10.1038/s41569-025-01124-3. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39875552/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39875552</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01124-3>10.1038/s41569-025-01124-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39875552</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Massimo Imazio</dc:creator>
<dc:creator>Federico Ballacci</dc:creator>
<dc:creator>Federica Giordano</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Colchicine in acute coronary syndromes: the present and the possible future</dc:title>
<dc:identifier>pmid:39875552</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01124-3</dc:identifier>
</item>
<item>
<title>Incident heart failure and recurrent coronary events following acute myocardial infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39874177/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In a contemporary post-MI cohort, the risk for incident HF was greater than recurrent MI, even among those with normal EF and no HF at discharge.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 28:ehae885. doi: 10.1093/eurheartj/ehae885. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Recurrent myocardial infarction (MI) and incident heart failure (HF) are major post-MI complications. Herein, contemporary post-MI risks for recurrent MI and HF are described.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 6804 patients with a primary discharge diagnosis of MI at 28 Baylor Scott &amp; White Health hospitals (January 2015 to December 2021) were studied. Patient characteristics, treatment, and outcomes, including incident HF, recurrent MI, all-cause death, and all-cause and cardiovascular rehospitalizations, were assessed. Landmark approach anchored at 3 months post-discharge was used to assess 1-year outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Median age was 69 years, 59.7% were male, and 76.7% had non-ST-elevation MI. Comorbidities included hypertension (89%), dyslipidaemia (87%), Type 2 diabetes (48%), and chronic kidney disease (34%); 17% had a history of MI and 23% of HF; 63% underwent percutaneous/surgical revascularization. In landmark-anchored 1-year outcomes (N = 6210), 413 (6.7%) patients died, 1730 (27.9%) had all-cause and 735 (11.8%) cardiovascular hospitalizations, 234 (3.8%) had recurrent MI. Of patients without history of HF, 1160 (23.8%) developed incident HF [42.2%, 26.7%, and 31.1% with ejection fraction (EF) &lt; 40%, 41-49%, and >;50%, respectively) within 3 months of discharge. Patients who developed HF had higher risk of death and hospitalizations (all P &lt; .001), irrespective of EF. Of 2179 patients with EF >; 50% without prevalent HF or HF during index hospitalization, 257 (11.8%) developed HF and 77 (3.5%) recurrent MI within 1 year.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In a contemporary post-MI cohort, the risk for incident HF was greater than recurrent MI, even among those with normal EF and no HF at discharge.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39874177/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39874177</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae885>10.1093/eurheartj/ehae885</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39874177</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Kendall Hammonds</dc:creator>
<dc:creator>Khawaja M Talha</dc:creator>
<dc:creator>Ayman Alhamdow</dc:creator>
<dc:creator>Monica M Bennett</dc:creator>
<dc:creator>J Vee Anne Bomar</dc:creator>
<dc:creator>Jason A Ettlinger</dc:creator>
<dc:creator>Monica Martinez Traba</dc:creator>
<dc:creator>Elisa L Priest</dc:creator>
<dc:creator>Niklas Schmedt</dc:creator>
<dc:creator>Cecilia Zeballos</dc:creator>
<dc:creator>Courtney N Shaver</dc:creator>
<dc:creator>Aasim Afzal</dc:creator>
<dc:creator>Robert J Widmer</dc:creator>
<dc:creator>Robert L Gottlieb</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Incident heart failure and recurrent coronary events following acute myocardial infarction</dc:title>
<dc:identifier>pmid:39874177</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae885</dc:identifier>
</item>
<item>
<title>Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-label ARIVA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39874026/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The overall primary patency rate during the first six months following endovascular intervention for PTS was higher than expected and comparable between patients receiving aspirin combined with rivaroxaban and those receiving rivaroxaban alone.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 28. doi: 10.1161/CIRCULATIONAHA.124.073050. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In patients with post-thrombotic syndrome (PTS), stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first 6 months after intervention. The ARIVA trial tested whether daily aspirin 100 mg plus rivaroxaban 20 mg is superior to rivaroxaban 20 mg alone to prevent stent thrombosis within 6 months after stent placement for PTS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this multinational, academic, open-label, independently adjudicated trial, patients with a Villalta score >;4 points, a stenosis or occlusion of the inferior vena cava, iliac veins, or common femoral vein, successfully treated with venous stent placement, were randomized in a 1:1 fashion to the study groups. Key exclusion criteria included age &lt;18 or >;75 years, contraindications to anticoagulant use or acute venous thrombosis &lt;3 months. The primary efficacy outcome was the composite of no occlusion in the treated segment assessed at serial duplex ultrasound examinations or no re-intervention needed to maintain patency within 6 months. Secondary outcomes, including Villalta score, quality of life, and safety outcomes were also assessed. The study was registered in ClinicalTrials.gov (NCT04128956).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From 2020 through 2022, 172 patients were screened, 169 randomized and 162 included in the full analysis set, receiving either aspirin plus rivaroxaban (n=80) or rivaroxaban alone (n=82) for six months. Mean age was 42.8 (standard deviation 14.7) years, 103 (60.9%) patients were women, 154 (97.5%) were Caucasian, and leg ulcers were present in 7% patients. The primary patency rate at six months was 94.8% vs. 92.4% (absolute risk difference: 2.4%; 95 %CI -13.6%; +18.0%), respectively. The mean decrease in the Villalta score for the affected leg (without ulcer) from baseline to 6 months was -6.7 (SD 4.4) and -7.0 (SD 5.2) points (p-value 0.36), respectively. There were no differences in other outcomes or quality of life at 6 months. No major bleeding occurred.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The overall primary patency rate during the first six months following endovascular intervention for PTS was higher than expected and comparable between patients receiving aspirin combined with rivaroxaban and those receiving rivaroxaban alone.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39874026/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39874026</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.073050>10.1161/CIRCULATIONAHA.124.073050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39874026</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Stefano Barco</dc:creator>
<dc:creator>Houman Jalaie</dc:creator>
<dc:creator>Tim Sebastian</dc:creator>
<dc:creator>Simon Wolf</dc:creator>
<dc:creator>Riccardo M Fumagalli</dc:creator>
<dc:creator>Michael Lichtenberg</dc:creator>
<dc:creator>Thomas Zeller</dc:creator>
<dc:creator>Christian Erbel</dc:creator>
<dc:creator>Oliver Schlager</dc:creator>
<dc:creator>Nils Kucher</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-label ARIVA Trial</dc:title>
<dc:identifier>pmid:39874026</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.073050</dc:identifier>
</item>
<item>
<title>Tricuspid regurgitation and outcomes in mitral valve transcatheter edge-to-edge repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39873695/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Post-procedural TR, but not baseline TR, was associated with outcomes after M-TEER. Careful TR assessment after the procedure would provide an optimal management for concomitant significant TR in patients undergoing M-TEER.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 28:ehae924. doi: 10.1093/eurheartj/ehae924. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The association between periprocedural change in tricuspid regurgitation (TR) and outcomes in patients undergoing mitral transcatheter edge-to-edge repair (M-TEER) is unclear. This study aimed to examine the prognostic value of TR before and after M-TEER.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients in the OCEAN-Mitral registry were divided into four groups according to baseline and post-procedure echocardiographic assessments: no TR/no TR (no TR), no TR/significant TR (new-onset TR), significant TR/no TR (normalized TR), and significant TR/significant TR (residual TR) (all represents before/after M-TEER). Tricuspid regurgitation ≥ moderate was defined as significant. The primary outcome was cardiovascular death or heart failure hospitalization. Tricuspid regurgitation pressure gradient was also evaluated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The numbers of patients in each group were 2103 (no TR), 201 (new-onset TR), 504 (normalized TR), and 858 (residual TR). Baseline assessment for TR and TR pressure gradient was not associated with outcomes after M-TEER. In contrast, patients with new-onset TR had the highest adjusted risk for the primary outcome, followed by those with residual TR [compared with no TR as a reference, hazard ratio 1.83 (95% confidence interval: 1.39-2.40) for new-onset TR, 1.45 (1.23-1.72) for residual TR, and 0.82 (0.65-1.04) for normalized TR]. Similarly, from baseline to post-procedure, TR pressure gradient changes were associated with subsequent outcomes after M-TEER. New-onset and residual TR incidence was commonly associated with dilated tricuspid annulus diameter and atrial fibrillation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Post-procedural TR, but not baseline TR, was associated with outcomes after M-TEER. Careful TR assessment after the procedure would provide an optimal management for concomitant significant TR in patients undergoing M-TEER.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39873695/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39873695</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae924>10.1093/eurheartj/ehae924</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39873695</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Shingo Matsumoto</dc:creator>
<dc:creator>Yohei Ohno</dc:creator>
<dc:creator>Satoshi Noda</dc:creator>
<dc:creator>Junichi Miyamoto</dc:creator>
<dc:creator>Norihiko Kamioka</dc:creator>
<dc:creator>Tsutomu Murakami</dc:creator>
<dc:creator>Yuji Ikari</dc:creator>
<dc:creator>Shunsuke Kubo</dc:creator>
<dc:creator>Yuki Izumi</dc:creator>
<dc:creator>Mike Saji</dc:creator>
<dc:creator>Masanori Yamamoto</dc:creator>
<dc:creator>Masahiko Asami</dc:creator>
<dc:creator>Yusuke Enta</dc:creator>
<dc:creator>Shinichi Shirai</dc:creator>
<dc:creator>Masaki Izumo</dc:creator>
<dc:creator>Shingo Mizuno</dc:creator>
<dc:creator>Yusuke Watanabe</dc:creator>
<dc:creator>Makoto Amaki</dc:creator>
<dc:creator>Kazuhisa Kodama</dc:creator>
<dc:creator>Junichi Yamaguchi</dc:creator>
<dc:creator>Toru Naganuma</dc:creator>
<dc:creator>Hiroki Bota</dc:creator>
<dc:creator>Masahiro Yamawaki</dc:creator>
<dc:creator>Hiroshi Ueno</dc:creator>
<dc:creator>Kazuki Mizutani</dc:creator>
<dc:creator>Daisuke Hachinohe</dc:creator>
<dc:creator>Toshiaki Otsuka</dc:creator>
<dc:creator>Kentaro Hayashida</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Tricuspid regurgitation and outcomes in mitral valve transcatheter edge-to-edge repair</dc:title>
<dc:identifier>pmid:39873695</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae924</dc:identifier>
</item>
<item>
<title>Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39873282/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In PARAGON-HF, in contrast with BMI, nearly every patient with HFpEF had central adiposity (as assessed by WHtR), and the risks of adverse heart failure events were more robustly related to WHtR. These data challenge the current reliance on BMI as an appropriate metric of adiposity, and they suggest that-rather than obesity-related HFpEF being regarded as a select HFpEF subgroup-central adiposity is a ubiquitous feature of HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 28:ehaf057. doi: 10.1093/eurheartj/ehaf057. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: An expansion of fat mass is an integral feature of patients with heart failure and preserved ejection fraction (HFpEF). While body mass index (BMI) is the most common anthropometric measure, a measure of central adiposity-the waist-to-height ratio (WHtR)-focuses on body fat content and distribution; is not distorted by bone or muscle mass, sex, or ethnicity; and may be particularly relevant in HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The PARAGON-HF trial randomized 4796 patients with heart failure and ejection fraction ≥45% to valsartan or sacubitril/valsartan. The current work characterizes the association of BMI and WHtR with clinical features, outcomes, and the response to neprilysin inhibition.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: About half (49%) of the participants were considered obese by BMI (≥30 kg/m2), but nearly every patient (96%) had central adiposity (WHtR ≥0.5). Among patients who were not obese (BMI &lt;30 kg/m2), 860 (37%) had marked central adiposity (WHtR ≥0.6). Higher BMI and WHtR were both associated with higher risk of total heart failure hospitalizations, but as compared with BMI, WHtR was linearly associated with heart failure outcomes and identified a higher proportion of patients who had a particularly elevated risk (i.e., 30% or greater). An obesity-survival paradox (i.e., improved outcomes in those with greater adiposity) was apparent with BMI in unadjusted analyses, but it was not observed with WHtR. Although neprilysin inhibition appeared to have greater effects on heart failure outcomes in patients with higher BMI and WHtR, analyses of interaction with obesity metrics did not show significant heterogeneity across the range of values for adiposity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In PARAGON-HF, in contrast with BMI, nearly every patient with HFpEF had central adiposity (as assessed by WHtR), and the risks of adverse heart failure events were more robustly related to WHtR. These data challenge the current reliance on BMI as an appropriate metric of adiposity, and they suggest that-rather than obesity-related HFpEF being regarded as a select HFpEF subgroup-central adiposity is a ubiquitous feature of HFpEF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39873282/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39873282</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf057>10.1093/eurheartj/ehaf057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39873282</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Alexander Peikert</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Ian J Kulac</dc:creator>
<dc:creator>Sheldon Litwin</dc:creator>
<dc:creator>Michael Zile</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Jawad H Butt</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Felipe Martinez</dc:creator>
<dc:creator>Dirk J Van Veldhuisen</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Jean Rouleau</dc:creator>
<dc:creator>Martin Lefkowitz</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial</dc:title>
<dc:identifier>pmid:39873282</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf057</dc:identifier>
</item>
<item>
<title>Prevent peripheral arterial disease and remain alive!</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39873235/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 28:ehae934. doi: 10.1093/eurheartj/ehae934. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39873235/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39873235</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae934>10.1093/eurheartj/ehae934</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39873235</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Christine Espinola-Klein</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Prevent peripheral arterial disease and remain alive!</dc:title>
<dc:identifier>pmid:39873235</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae934</dc:identifier>
</item>
<item>
<title>Bromocriptine in the treatment of peripartum cardiomyopathy: is it ready for prime time?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39873231/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 28:ehae875. doi: 10.1093/eurheartj/ehae875. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39873231/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39873231</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae875>10.1093/eurheartj/ehae875</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39873231</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Uri Elkayam</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Bromocriptine in the treatment of peripartum cardiomyopathy: is it ready for prime time?</dc:title>
<dc:identifier>pmid:39873231</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae875</dc:identifier>
</item>
<item>
<title>CCN5 suppresses injury-induced vascular restenosis by inhibiting smooth muscle cell proliferation and facilitating endothelial repair via thymosin β4 and Cd9 pathway</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39873228/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: CCN5 exerts a dual protective effect on ISR by inhibiting VSMC proliferation and facilitating EC repair. CCN5rp-coated stent might be promising in the prevention of ISR after PCI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 28:ehae911. doi: 10.1093/eurheartj/ehae911. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Members of the CCN matricellular protein family are crucial in various biological processes. This study aimed to characterize vascular cell-specific effects of CCN5 on neointimal formation and its role in preventing in-stent restenosis (ISR) after percutaneous coronary intervention (PCI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Stent-implanted porcine coronary artery RNA-seq and mouse injury-induced femoral artery neointima single-cell RNA sequencing were performed. Plasma CCN5 levels were measured by enzyme-linked immunosorbent assay. Endothelial cell (EC)- and vascular smooth muscle cell (VSMC)-specific CCN5 loss-of-function and gain-of-function mice were generated. Mass spectrometry and co-immunoprecipitation were conducted to identify CCN5 interacting proteins. Additionally, CCN5 recombinant protein (CCN5rp)-coated stents were deployed to evaluate its anti-ISR effects in a porcine model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Plasma CCN5 levels were significantly reduced and correlated closely with the degree of restenosis in ISR patients. CCN5 expression was significantly decreased in VSMCs of stent-implanted porcine coronary segments and injured mouse femoral arteries, especially in synthetic VSMCs. In contrast, elevated CCN5 expression was observed in regenerating ECs of injured vessels. Endothelial cell- and VSMC-specific CCN5 deletion mice exhibited exacerbation of injury-induced neointimal hyperplasia, while CCN5 gain-of-function alleviated neointimal formation. Mechanistic studies identified thymosin β4 (Tβ4) as a CCN5 interacting protein in ECs and EC-CCN5 promoted injury repair through Tβ4 cleavage product Ac-SDKP. Also, CCN5rp promoted EC repair to suppress neointimal hyperplasia via interaction with Cd9 extracellular domain. Moreover, implantation with CCN5rp-coated stent significantly increased stent strut coverage with ECs, which suppressed neointimal formation and ultimately alleviated ISR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CCN5 exerts a dual protective effect on ISR by inhibiting VSMC proliferation and facilitating EC repair. CCN5rp-coated stent might be promising in the prevention of ISR after PCI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39873228/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39873228</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae911>10.1093/eurheartj/ehae911</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39873228</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Qi Zhang</dc:creator>
<dc:creator>Hongda Li</dc:creator>
<dc:creator>Tao Zhuang</dc:creator>
<dc:creator>Lehua Xu</dc:creator>
<dc:creator>Wenrun Wu</dc:creator>
<dc:creator>Jingjiang Pi</dc:creator>
<dc:creator>Pengxiong Zhu</dc:creator>
<dc:creator>Liang Geng</dc:creator>
<dc:creator>Yunhao Duan</dc:creator>
<dc:creator>Jianfei Xu</dc:creator>
<dc:creator>Jinnan Yue</dc:creator>
<dc:creator>Xiuxiang Liu</dc:creator>
<dc:creator>Chenlong He</dc:creator>
<dc:creator>Xiaoli Chen</dc:creator>
<dc:creator>Chengchao Ruan</dc:creator>
<dc:creator>Shougang Zhuang</dc:creator>
<dc:creator>Zhongmin Liu</dc:creator>
<dc:creator>Yilong Wang</dc:creator>
<dc:creator>Lin Zhang</dc:creator>
<dc:creator>Jie Liu</dc:creator>
<dc:creator>Yuzhen Zhang</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>CCN5 suppresses injury-induced vascular restenosis by inhibiting smooth muscle cell proliferation and facilitating endothelial repair via thymosin β4 and Cd9 pathway</dc:title>
<dc:identifier>pmid:39873228</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae911</dc:identifier>
</item>
<item>
<title>The year in cardiovascular medicine 2024: the top 10 papers in cardio-oncology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39873207/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 28:ehaf019. doi: 10.1093/eurheartj/ehaf019. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39873207/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39873207</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf019>10.1093/eurheartj/ehaf019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39873207</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Joerg Herrmann</dc:creator>
<dc:creator>Teresa López-Fernández</dc:creator>
<dc:creator>Alexander R Lyon</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2024: the top 10 papers in cardio-oncology</dc:title>
<dc:identifier>pmid:39873207</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf019</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: Is left atrial appendage closure a safe and effective OPTION after ablation for atrial fibrillation?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39871755/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 28:ehae922. doi: 10.1093/eurheartj/ehae922. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39871755/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39871755</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae922>10.1093/eurheartj/ehae922</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39871755</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: Is left atrial appendage closure a safe and effective OPTION after ablation for atrial fibrillation?</dc:title>
<dc:identifier>pmid:39871755</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae922</dc:identifier>
</item>
<item>
<title>Cardiorespiratory Fitness Assessment in Stem Cell Transplant Recipients: Getting to the Heart of the Problem</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39869673/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 28;151(4):309-311. doi: 10.1161/CIRCULATIONAHA.124.072547. Epub 2025 Jan 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39869673/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39869673</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072547>10.1161/CIRCULATIONAHA.124.072547</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39869673</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Justin M Canada</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiorespiratory Fitness Assessment in Stem Cell Transplant Recipients: Getting to the Heart of the Problem</dc:title>
<dc:identifier>pmid:39869673</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072547</dc:identifier>
</item>
<item>
<title>SLICE-CEA CardioLink-8: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Characteristics in Asymptomatic High-Risk Carotid Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39869672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 28;151(4):351-355. doi: 10.1161/CIRCULATIONAHA.124.072285. Epub 2025 Jan 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39869672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39869672</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072285>10.1161/CIRCULATIONAHA.124.072285</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39869672</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>C David Mazer</dc:creator>
<dc:creator>Alan R Moody</dc:creator>
<dc:creator>Hwee Teoh</dc:creator>
<dc:creator>Adrian Quan</dc:creator>
<dc:creator>Randi Elituv</dc:creator>
<dc:creator>Thayalasuthan Vivekanandan</dc:creator>
<dc:creator>Peiyu Li</dc:creator>
<dc:creator>Kevin E Thorpe</dc:creator>
<dc:creator>Myriam Lafreniere-Roula</dc:creator>
<dc:creator>Raj Verma</dc:creator>
<dc:creator>Michael Moroney</dc:creator>
<dc:creator>Jack H Casey</dc:creator>
<dc:creator>Navneet Singh</dc:creator>
<dc:creator>Aditya Bharatha</dc:creator>
<dc:creator>Rasha Mahmoud</dc:creator>
<dc:creator>Regis Manorajah</dc:creator>
<dc:creator>Andrew Jayarajah</dc:creator>
<dc:creator>Anish N Kapadia</dc:creator>
<dc:creator>Andrew D Dueck</dc:creator>
<dc:creator>Mohammed Al-Omran</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Lawrence A Leiter</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>SLICE-CEA CardioLink-8: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Characteristics in Asymptomatic High-Risk Carotid Stenosis</dc:title>
<dc:identifier>pmid:39869672</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072285</dc:identifier>
</item>
<item>
<title>Kidney Decline Predicts Worse Heart Failure Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39869671/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 28;151(4):348-350. doi: 10.1161/CIRCULATIONAHA.124.072099. Epub 2025 Jan 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39869671/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39869671</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072099>10.1161/CIRCULATIONAHA.124.072099</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39869671</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Bridget M Kuehn</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Kidney Decline Predicts Worse Heart Failure Outcomes</dc:title>
<dc:identifier>pmid:39869671</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072099</dc:identifier>
</item>
<item>
<title>Response by Hoeper et al to Letter Regarding Article, "Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults with Pulmonary Arterial Hypertension"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39869670/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 28;151(4):e32. doi: 10.1161/CIRCULATIONAHA.124.072235. Epub 2025 Jan 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39869670/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39869670</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072235>10.1161/CIRCULATIONAHA.124.072235</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39869670</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Marius M Hoeper</dc:creator>
<dc:creator>Scott Haughie</dc:creator>
<dc:creator>Tarek Hassan</dc:creator>
<dc:creator>Susanne Vogt</dc:creator>
<dc:creator>Sarah Hackley</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Hoeper et al to Letter Regarding Article, "Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults with Pulmonary Arterial Hypertension"</dc:title>
<dc:identifier>pmid:39869670</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072235</dc:identifier>
</item>
<item>
<title>Relatively Increased CO&lt;sub>;2&lt;/sub>; Delivered to the Brain From the Descending Aorta Leading to an Elevated Respiratory Rate Causing Differential Hypocapnia (RIDDLER or East-West Syndrome): New Pitfalls in Awake Peripheral V-A ECMO</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39869669/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 28;151(4):289-291. doi: 10.1161/CIRCULATIONAHA.124.071524. Epub 2025 Jan 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39869669/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39869669</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071524>10.1161/CIRCULATIONAHA.124.071524</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39869669</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Alex Rosenberg</dc:creator>
<dc:creator>Louit Thakuria</dc:creator>
<dc:creator>Christophe Vandenbriele</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Relatively Increased CO&lt;sub>;2&lt;/sub>; Delivered to the Brain From the Descending Aorta Leading to an Elevated Respiratory Rate Causing Differential Hypocapnia (RIDDLER or East-West Syndrome): New Pitfalls in Awake Peripheral V-A ECMO</dc:title>
<dc:identifier>pmid:39869669</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071524</dc:identifier>
</item>
<item>
<title>Letter by Yan et al Regarding Article, "Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39869668/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 28;151(4):e31. doi: 10.1161/CIRCULATIONAHA.124.071712. Epub 2025 Jan 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39869668/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39869668</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071712>10.1161/CIRCULATIONAHA.124.071712</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39869668</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Peijing Yan</dc:creator>
<dc:creator>Min Zhang</dc:creator>
<dc:creator>Yunshan Cao</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Yan et al Regarding Article, "Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension"</dc:title>
<dc:identifier>pmid:39869668</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071712</dc:identifier>
</item>
<item>
<title>State of the Heart (and Brain) in 2025</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39866123/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 27. doi: 10.1161/CIRCULATIONAHA.125.073826. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39866123/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39866123</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.073826>10.1161/CIRCULATIONAHA.125.073826</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39866123</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>State of the Heart (and Brain) in 2025</dc:title>
<dc:identifier>pmid:39866123</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.073826</dc:identifier>
</item>
<item>
<title>2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39866113/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250129091008&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The Statistical Update represents a critical resource for the lay public, policymakers, media professionals, clinicians, health care administrators, researchers, health advocates, and others seeking the best available data on these factors and conditions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 27. doi: 10.1161/CIR.0000000000001303. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The American Heart Association (AHA), in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, nutrition, sleep, and obesity) and health factors (cholesterol, blood pressure, glucose control, and metabolic syndrome) that contribute to cardiovascular health. The AHA Heart Disease and Stroke Statistical Update presents the latest data on a range of major clinical heart and circulatory disease conditions (including stroke, brain health, complications of pregnancy, kidney disease, congenital heart disease, rhythm disorders, sudden cardiac arrest, subclinical atherosclerosis, coronary heart disease, cardiomyopathy, heart failure, valvular disease, venous thromboembolism, and peripheral artery disease) and the associated outcomes (including quality of care, procedures, and economic costs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing. The 2025 AHA Statistical Update is the product of a full year's worth of effort in 2024 by dedicated volunteer clinicians and scientists, committed government professionals, and AHA staff members. This year's edition includes a continued focus on health equity across several key domains and enhanced global data that reflect improved methods and incorporation of ≈3000 new data sources since last year's Statistical Update.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Each of the chapters in the Statistical Update focuses on a different topic related to heart disease and stroke statistics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The Statistical Update represents a critical resource for the lay public, policymakers, media professionals, clinicians, health care administrators, researchers, health advocates, and others seeking the best available data on these factors and conditions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39866113/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250129091008&v=2.18.0.post9+e462414">39866113</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001303>10.1161/CIR.0000000000001303</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39866113</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Seth S Martin</dc:creator>
<dc:creator>Aaron W Aday</dc:creator>
<dc:creator>Norrina B Allen</dc:creator>
<dc:creator>Zaid I Almarzooq</dc:creator>
<dc:creator>Cheryl A M Anderson</dc:creator>
<dc:creator>Pankaj Arora</dc:creator>
<dc:creator>Christy L Avery</dc:creator>
<dc:creator>Carissa M Baker-Smith</dc:creator>
<dc:creator>Nisha Bansal</dc:creator>
<dc:creator>Andrea Z Beaton</dc:creator>
<dc:creator>Yvonne Commodore-Mensah</dc:creator>
<dc:creator>Maria E Currie</dc:creator>
<dc:creator>Mitchell S V Elkind</dc:creator>
<dc:creator>Wenjun Fan</dc:creator>
<dc:creator>Giuliano Generoso</dc:creator>
<dc:creator>Bethany Barone Gibbs</dc:creator>
<dc:creator>Debra G Heard</dc:creator>
<dc:creator>Swapnil Hiremath</dc:creator>
<dc:creator>Michelle C Johansen</dc:creator>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:creator>Darae Ko</dc:creator>
<dc:creator>Michelle H Leppert</dc:creator>
<dc:creator>Jared W Magnani</dc:creator>
<dc:creator>Erin D Michos</dc:creator>
<dc:creator>Michael E Mussolino</dc:creator>
<dc:creator>Nisha I Parikh</dc:creator>
<dc:creator>Sarah M Perman</dc:creator>
<dc:creator>Mary Rezk-Hanna</dc:creator>
<dc:creator>Gregory A Roth</dc:creator>
<dc:creator>Nilay S Shah</dc:creator>
<dc:creator>Mellanie V Springer</dc:creator>
<dc:creator>Marie-Pierre St-Onge</dc:creator>
<dc:creator>Evan L Thacker</dc:creator>
<dc:creator>Sarah M Urbut</dc:creator>
<dc:creator>Harriette G C Van Spall</dc:creator>
<dc:creator>Jenifer H Voeks</dc:creator>
<dc:creator>Seamus P Whelton</dc:creator>
<dc:creator>Nathan D Wong</dc:creator>
<dc:creator>Sally S Wong</dc:creator>
<dc:creator>Kristine Yaffe</dc:creator>
<dc:creator>Latha P Palaniappan</dc:creator>
<dc:creator>American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Committee</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association</dc:title>
<dc:identifier>pmid:39866113</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001303</dc:identifier>
</item>





























</channel>
</rss>